Drug Database
Back to search

Poland· PL-100247068

Glibenese GITS

A glipizide product containing glipizidum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 8 of our 19 countries.

ATC A10BB07

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedGlibenese GITSATCA10BB07REGISTER NO.PL-100247068PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glipizidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glipizide is registered in 8 of 19 countries.

Countries holding a registration under ATC A10BB07 (glipizide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search glipizide products by name

Glipizide · ATC A10BB07

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Italyprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of glipizide costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.056 in United States to $0.39 in France — a ×7.0 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Glipizide · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • FR France$0.39
  • IT Italy$0.32
  • US United States$0.056 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Glipizidum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
A10BB07
ATC class
Glipizide
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990792818
  • gtin
    05909990792825

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

745 interactions on record for glipizide.

Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check glipizide against other medicinesHow interaction checks work

Glipizide · interactions on record

745 records

  • 20 severe
  • 448 moderate
  • 51 minor
  • 226 info

Most severe, free to view

  • MiconazoleA07AC01severe
  • Magnesium carbonateA02AA01moderate
  • Magnesium oxideA02AA02moderate
  • Magnesium hydroxideA02AA04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glipizide in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glipizide products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Czechia · Minidiab
  • Spain · Minodiab
  • France · Ozidia
  • United Kingdom (Northern Ireland) · Minodiab
  • Italy · Minidiab
  • Romania · Glucotrol Xl

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9bb6d457-56d2-4f92-bf6e-36e197488aa1
GET /v1/drugs/9bb6d457-56d2-4f92-bf6e-36e197488aa1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki o przedłużonym uwalnianiu",
  "source": "urpl",
  "strength": "10 mg",
  "packaging": "05909990792818 ¦ Rp ¦ 12605\n30 tabl.\n05909990792825 ¦ Rp ¦ Skasowane ¦ 20219\n10 tabl.",
  "substance": "Glipizidum 10.98 mg",
  "common_name": "Glipizidum",
  "pl_product_id": "100247068",
  "pozwolenie_nr": "07928",
  "auth_procedure": "NAR",
  "authorisation_validity": "2024-10-31"
}
API referenceMCP serverPlans

See everything about glipizide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console